ASH 2023 | Novel combination therapy for CMML: JAK inhibitor pacritinib plus azacitidine
Douglas Tremblay, MD, Icahn School of Medicine at Mount Sinai, New York, NY, outlines the Phase I/II study (NCT06159491) of the JAK inhibitor pacritinib in combination with azacitidine in chronic myelomonocytic leukemia (CMML). There is a lack of effective treatment options for CMML, and evidence from cell models suggests a synergistic effect when pacritinib and azacitidine are combined. The trial will assess the use of this combination therapy in addition to hypomethylating agents (HMAs), the current standard of care. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
